The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ESH 2019 | Is AML susceptible to immunotherapy?

Oct 31, 2019

The AML Global Portal were delighted to speak to John DiPersio, Washington University Medical School, St. Louis, US, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked John DiPersio: Is AML susceptible to immunotherapy? He outlined the current challenges of immunotherapeutic approaches in AML, such as lack of selective targets and life-threatening side-effects, and how they can potentially be overcome.

Is AML susceptible to immunotherapy?